Bovespa Index Ends the Quarter 4.53% Lower at 128106.10 — Data Talk
The Bovespa Index is down 6079.14 points or 4.53% this quarter to 128106.10
--Largest one-quarter point and percentage decline since the 1st quarter 2023
--Down four of the past six quarters
--This month it is down 913.92 points or 0.71%
--Largest one-month point and percentage decline since Jan. 2024
--Down two of the past three months
--This week it is up 1079.00 points or 0.85%
--Largest one-week point and percentage gain since the week ending Jan 26, 2024
--Up for two consecutive weeks
--Up 1364.29 points or 1.08% over the last two weeks
--Largest two-week point and percentage gain since the week ending Feb 23, 2024
--Today it is up 415.48 points or 0.33%
--Up for two consecutive trading days
--Up 1243.08 points or 0.98% over the last two trading days
--Largest two-day point and percentage gain since Wednesday, March 20, 2024
--Off 4.54% from its record close of 134193.72 hit Wednesday, Dec. 27, 2023
--Highest closing value since Thursday, March 21, 2024
--Off 4.54% from its 52-week high of 134193.72 hit Wednesday, Dec. 27, 2023
--Up 27.06% from its 52-week low of 100821.73 hit Thursday, April 6, 2023
--Rose 23.52% from 52 weeks ago
--Off 3.56% from its 2024 closing high of 132833.95 hit Wednesday, Jan 3, 2024
--Up 1.57% from its 2024 closing low of 126123.56 hit Monday, March 11, 2024
--Year-to-date it is down 6079.14 points or 4.53%
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
March 28, 2024 17:22 ET (21:22 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth